cyanotic heart disease

Cardiovascular disease trials address coronary artery disease, heart failure, atrial fibrillation, and acute coronary syndromes — collectively the leading cause of mortality globally. After decades of incremental improvement in lipid-lowering and antithrombotic therapy, the field is now exploring RNA-based therapies, gene editing, and cardiac regeneration approaches.

Active research includes PCSK9 inhibitors and inclisiran for LDL reduction, SGLT2 inhibitors in heart failure with preserved ejection fraction (HFpEF), mavacamten for hypertrophic cardiomyopathy, cardiac stem cell therapies, and AI-guided device therapies. Wearables and remote monitoring are also being validated as clinical endpoints.

Enrollment eligibility typically depends on left ventricular ejection fraction (LVEF), NT-proBNP levels, and prior cardiovascular events.